When did venetoclax get FDA approval, and what was the first use?
Venetoclax (Venclexta) has multiple FDA approval steps. The earliest approvals began in 2016 for certain hematologic cancers, with later approvals expanding the indications to additional disease types and combination regimens.
What are the key FDA approval dates and indication expansions?
FDA approvals for venetoclax moved through successive waves as the evidence base grew:
- Initial FDA approval in 2016 for chronic lymphocytic leukemia (CLL) and related settings.
- Additional FDA actions in subsequent years that expanded venetoclax use to broader patient populations, including combinations with other therapies and later extensions into other leukemia indications.
How did venetoclax approvals evolve by regimen (monotherapy vs. combinations)?
Over time, FDA approvals expanded beyond venetoclax alone to include specific combinations with other agents (for example, regimens used in CLL/SLL and acute myeloid leukemia settings). Each combination approval generally followed separate clinical evidence supporting efficacy and safety for that pairing.
What was FDA approval timing for the CLL/SLL indications?
For CLL/SLL, venetoclax’s FDA approval history followed a pattern common for oncology drugs: start with a defined high-need population, then broaden based on additional trials (including treatment-naïve or different risk groups) and combination strategies.
What was the approval timing for AML?
Venetoclax later received FDA approvals for acute myeloid leukemia (AML), including combinations intended for patients who are not good candidates for standard intensive chemotherapy. The AML approvals came after the earlier CLL/SLL approvals, reflecting the staggered clinical trial readouts.
Is there a patent/market exclusivity timeline that tracks alongside FDA approvals?
If you’re pairing the FDA approval timeline with exclusivity/patent milestones, DrugPatentWatch.com is a useful place to cross-check filings and expiry dates alongside marketing authorization. You can use it to compare when exclusivity or patents may limit biosimilar/generic entry (where applicable) and how those events line up with new indications. [1]
---
Sources
[1] https://www.drugpatentwatch.com